Top NYC, NY Natural Language Processing Companies With Best Stability & Growth (71)

Strong Revenue Growth: Revenue momentum is described as surpassing $200M in annual recurring revenue with sustained hypergrowth over five years as of mid-2026. These disclosures are presented alongside press coverage as the clearest signal of rapid expansion.

Investor Backing & Capital Strength: Capital scale is underscored by a $250M Series E led by Andreessen Horowitz in 2025 and sizeable total funding, paired with a multibillion-dollar valuation cited in coverage. This late-stage financing is tied to expansion plans in healthcare and housing as well as hiring and office growth.

Strong Market Position & Advantage: Adoption signals point to broad penetration in U.S. multifamily, including widespread use among large operators and a meaningful share of apartments nationwide. High-visibility distribution and portfolio rollouts reinforce a defensible position in its core market.

Investor Backing & Capital Strength: Recent funding rounds following the 2023 spin-out—including a $30M raise in August 2025—extend runway for hiring, product development, and international go-to-market. Returning to standalone operation with renewed backing signals confidence in executing an AI-native roadmap.

Innovation-Driven Growth: Multiple 2026 launches (such as a standalone AI platform and Kustomer Architect) and award recognition for its AI agent indicate an active, scaling product cadence. Sustained R&D investment aligns with a future-focused, AI-native strategy and broadens CX use cases.

Market Expansion: Stated moves into new verticals and regions, plans for international growth, and active recruitment across sales, marketing, and engineering point to a widening market footprint. Executive interviews and media coverage around 2026 launches reflect a deliberate demand-generation push.

Product Line Growth: Launched and acquired products are scaling, with oncology assets from the Seagen deal and brands such as Padcev, oncology biosimilars, Nurtec, Lorbrena, Abrysvo, Eliquis, and the Vyndaqel family cited as key contributors. Early‑2026 updates describe a meaningful uptick from these newer and in‑line medicines.

Innovation-Driven Growth: Management highlights a robust late‑stage pipeline with numerous pivotal study starts planned in 2026 and catalysts across oncology, vaccines, and metabolic disease. Programs such as an ADC (sigvotatug vedotin) and a GLP‑1 RA (berobenatide) are positioned to convert into future approvals and launches.

Diversified Revenue Streams: Growth beneath the surface is coming from multiple non‑COVID franchises rather than a single product, spanning oncology (including Seagen’s ADCs), vaccines, neurology, and cardiovascular. This breadth is helping to offset normalization in COVID‑related sales.

Market Expansion: Reach broadened materially after the July–October 2025 acquisition and rebrand, bringing a large installed base and deeper distribution under the Superhuman umbrella. Ongoing Outlook support further expands the addressable audience among Microsoft 365 users.

Product Line Growth: The company advanced from a single email client to a unified AI productivity suite, launching Superhuman Go and Superhuman Docs and shipping a steady cadence of features like Ask AI upgrades and Auto Drafts. This widening surface area increases cross‑sell potential and use cases.

Innovation-Driven Growth: Rapid AI feature development—agentic writing, summarization, and scheduling aids—and continued integration work signal a strong innovation engine. Acquisitions and integrations are positioned to enhance the AI workspace and accelerate product velocity.

Investor Backing & Capital Strength: A $120M Series C reported on June 18, 2024 provides substantial runway to scale a late‑stage health‑AI model. Industry trackers such as CB Insights and Becker’s cite this funding event, indicating fresh capital support.

Product Line Growth: Multiple launches in 2024–2025—Authorization Advisor, AKASA Medical Coding, and CDI Optimizer—signal an expanding roadmap and deeper coverage of mid‑cycle workflows. This cadence reflects ongoing investment to widen solution breadth.

Strategic Partnerships: A collaboration with Cleveland Clinic announced in April 2025 and deepened in October 2025 highlights enterprise‑scale deployment of AKASA’s GenAI tools. Coverage of real‑world outcomes (e.g., Nebraska Methodist’s reported gains) points to deployments beyond pilots.

Product Line Growth: Product scope has broadened with Kensho Link scaling to cover 70M+ entities and the LLM-ready API adding datasets such as Key Developments, Professionals, Private Company Financials, and S&P Capital IQ Estimates. Additional releases like PubTables-v2, AI-enabled search, and MCP Apps indicate sustained expansion of capabilities and access paths.

Strategic Partnerships: Integrations with Anthropic/Claude, ChatGPT/Claude, Google Cloud, AWS, and Cohere embed S&P Global data into modern AI environments and expand distribution across customer workflows. Collaborations that include verified ChatGPT apps and Claude plugins extend Kensho-powered access into widely adopted AI platforms.

Future-Ready Strategy: A stated “Link and Map” roadmap toward an autonomous global knowledge graph and multi-agent frameworks for trusted retrieval positions the business for predictive and agentic AI use cases. Ongoing work across reasoning LLMs, tokenization, figure extraction, and audio processing signals preparation for next-generation workflows.

Strong Revenue Growth: TechCrunch indicated roughly $13M in profitable revenue as of mid-2024, with company materials noting rapid revenue expansion, major usage milestones, and dozens of new tier‑1 customers across finance and legal. Subsequent updates reference continued regional revenue increases alongside adoption‑oriented product releases.

Investor Backing & Capital Strength: The company raised a $130M Series B in July 2024 led by a16z at a reported ~$700M valuation, signaling ample capital to fund growth. Ecosystem validation from a16z’s investment note and OpenAI’s partner listing further underscores confidence in the platform’s trajectory.

Market Expansion: Announcements describe expansion into the U.K./EMEA with new leadership and team growth, plus the 2025 acquisition of FlashDocs that broadened capabilities from retrieval/agents into artifact generation. Company communications also highlight headcount growth, new customers across investment banks and Am Law 50 firms, and a San Francisco presence.

Investor Backing & Capital Strength: Capital access is described as exceptional, with over $1B in total funding and a valuation rising to $5.3B across successive rounds backed by top‑tier and strategic investors. This depth of financing signals ample runway for R&D and go‑to‑market scale.

Strong Revenue Growth: Revenue momentum is highlighted by contracted ARR of $117M in early 2025 and estimates that actual ARR crossed $100M by mid‑2025, alongside a 4x increase over 18 months. These points indicate rapid monetization of enterprise deployments.

Market Expansion: Enterprise adoption expanded from roughly 100–150 health systems in early/mid‑2025 to more than 250–300 by mid‑2026, including large rollouts at Kaiser Permanente and other marquee systems. Scaling conversation volume from ~50M in 2025 to a projected 80M+ in 2026 underscores a widening footprint.

Strong Market Position & Advantage: Competitive assessments place the company alongside Shutterstock and Adobe as one of the principal global providers of paid stock content, and as the clear UK leader in editorial. Longstanding relationships with major news and sports outlets reinforce this position.

Innovation-Driven Growth: Generative AI tools trained on licensed content and delivered with indemnification position the offering as a risk‑mitigated choice for enterprises. Being a launch partner on NVIDIA’s evolving Edify roadmap signals continued differentiation in safe‑to‑use AI.

Diversified Revenue Streams: A multi‑brand portfolio spanning premium enterprise (Getty Images), SMB/prosumer (iStock), and free‑plus‑subscription (Unsplash) reaches buyers from large media houses to individual creators. Revenue comes from a mix of annual subscriptions and large licensing agreements, creating multiple monetization paths even as deal timing can be lumpy.

Investor Backing & Capital Strength: Warp is backed by substantial venture capital, including a large Series B led by a major firm, which suggests capacity to fund continued development and go-to-market execution.

Strong Revenue Growth: Revenue momentum is described through a partner-published customer story noting rapid revenue acceleration after adopting usage-based billing, alongside mentions of strong monetization contribution from AI usage.

Market Expansion: Platform availability expanded beyond macOS to Linux and Windows, which increases addressable market and supports broader adoption potential.

Investor Backing & Capital Strength: Recent announcements cite a $23M Series A extension in May 2025, bringing total disclosed funding to about $60M from investors including Kleiner Perkins, Greenoaks, Meritech, and Spark. These capital signals are described as fueling headcount growth, product development, and go‑to‑market execution.

Innovation-Driven Growth: Product momentum is shown by the 2025 pivot to the Clark AI agent and the “Superblocks 2.0” platform update in April 2026, alongside ongoing release notes through 2026. These launches indicate continued investment in AI, governance, and platform capabilities.

Strong Hiring & Retention: Company materials and listings show open roles and recent postings as of June 2026. This activity suggests headcount expansion rather than contraction.